Sign in
CompletedNo phase

Efficacy of Lentinula Edodes-Derived Supplement (AHCC®) in Promoting Negativity of Persistent HPV Infection

Key facts

Who runs it
Liaquat University of Medical & Health Sciences
Where
Italy1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
People taking part
289 people enrolled
Started
2 Jan 2023
Ended
15 Dec 2024
Type of study
Observational, 3 groups
Treatments tested
  • AHCC® (Active Hexose Correlated Compound)
  • Gardasil 9®
Record updated
28 January 2026

Who can take part

Age
18 years and older
Sex
Women only
Healthy volunteers
Cannot take part
Show the full registry criteria (11)Hide the full registry criteria

Who can take part

  • Female participants aged 18 years or older
  • Documented persistent high-risk HPV infection for at least 6 continuous months, confirmed by consecutive HPV-DNA tests
  • Absence of high-grade cervical lesions (≤ CIN1)
  • Availability of complete clinical records with evaluable HPV-DNA testing at baseline and follow-up
  • Documented management with AHCC® supplementation alone, nonavalent HPV vaccination alone, or combined AHCC® supplementation and nonavalent HPV vaccination in routine clinical practice
  • No prior excisional or ablative treatment of the cervix (including conization or LEEP)

Who cannot take part

  • History of cervical excisional or ablative treatment (including conization or LEEP)
  • Presence of high-grade cervical lesions (CIN2 or worse) or invasive cervical cancer
  • Conditions known to significantly alter immune function, including ongoing immunosuppressive therapy, active autoimmune disease requiring systemic treatment, or documented immunodeficiency, when such information was available in medical records
  • Prior systemic antiviral or immunomodulatory therapy specifically aimed at HPV clearance during the observation period
  • Incomplete clinical documentation or missing HPV follow-up data

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This is a retrospective, multicenter, observational study evaluating real-world HPV-DNA clearance in women with documented persistent high-risk HPV infection lasting at least six months. Clinical data were retrospectively collected from medical records of women managed in routine practice with one of three strategies: AHCC® supplementation alone, nonavalent HPV vaccination alone, or the combination of AHCC® supplementation and nonavalent HPV vaccination. The primary objective is to assess HPV-DNA clearance at 4 and 6 months following treatment initiation.

The 3 groups in the trial

  • Unvaccinated with AHCC® Supplement

    Women previously managed in routine clinical practice with AHCC® supplementation alone for persistent HPV infection. Participants had not received HPV vaccination prior to treatment. Clinical data were retrospectively collected from medical records to evaluate HPV-DNA clearance following this real-world management strategy.

    Treatment: AHCC® (Active Hexose Correlated Compound)

  • Vaccinated with AHCC® Supplement

    Women previously managed in routine clinical practice with combined AHCC® supplementation and nonavalent HPV vaccination for persistent HPV infection. Treatments were prescribed as part of standard care. Clinical data were retrospectively collected to assess HPV-DNA clearance following combined real-world exposure.

    Treatment: AHCC® (Active Hexose Correlated Compound) and Gardasil 9®

  • Vaccinated Only

    Women previously managed in routine clinical practice with nonavalent HPV vaccination alone for persistent HPV infection. No AHCC® supplementation was used. Clinical data were retrospectively collected to assess HPV-DNA clearance following vaccination as standard care.

    Treatment: Gardasil 9®

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Evaluation of the Efficacy and Safety of an AHCC®-Based Supplement (Lentinula Edodes) in Promoting Negativity of Persistent HPV Infection: A Retrospective Multicenter Clinical Study
Record updated
28 January 2026